(NASDAQ: AQST) Aquestive Therapeutics's forecast annual revenue growth rate of 16.1% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Aquestive Therapeutics's revenue in 2024 is $50,583,000.On average, 5 Wall Street analysts forecast AQST's revenue for 2024 to be $3,705,229,108, with the lowest AQST revenue forecast at $3,665,060,050, and the highest AQST revenue forecast at $3,799,201,248. On average, 4 Wall Street analysts forecast AQST's revenue for 2025 to be $4,163,141,711, with the lowest AQST revenue forecast at $3,650,399,810, and the highest AQST revenue forecast at $4,413,465,312.
In 2026, AQST is forecast to generate $6,129,886,235 in revenue, with the lowest revenue forecast at $5,497,590,075 and the highest revenue forecast at $7,138,070,953.